Considering that ARSA deficiency has been shown to be associated with an increase in α-synuclein aggregates12, these data indicated that the plasma level of ARSA, a lysosomal enzyme, is elevated in the early stage of PD, which could be a novel biomarker of the compensation of nigrostriatal degeneration. The gene discussed is ARSA; the disease is Parkinson disease.